Shares of Adamis crater on CRL; Boris Johnson promises to double dementia research funding
→ San Diego-based Adamis $ADMP saw its shares crater on the news that the FDA has rejected its application to market high-dose naloxone injection for the treatment of opioid overdose. The stock dropped about 50%, falling deep into penny stock territory. According to the biotech, the FDA had some outstanding questions on CMC that have to be resolved ahead of any approval.
→ After recently pledging £250 million into AI adoption in the NHS, UK Prime Minister Boris Johnson vowed in his manifesto unveiled on Sunday to invest an additional £83 million a year into dementia research, doubling current funding, over the next decade if the Conservative Party prevails in the general election. In addition, the Tories also promised to create a new £500 million fund for new medicines treating hard to cure diseases such as cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.